Category Variables in Responding and Nonresponding Patients
| Variable . | Favorable Group . | Response Rate (%) . | Unfavorable Group . | Response Rate (%) . | P Value . |
|---|---|---|---|---|---|
| Sex (M/F)* | Female | 38 | Male | 35 | .93 |
| Karyotype (N/A)3-151 | A | 41 | N | 38 | .81 |
| Pretreatment transfusions (yes/no) | no | 53.3 | yes | 28.6 | .09 |
| Pretreatment transfusions U/month | <2 | 50 | ≥2 | 21.7 | .04 |
| Serum epo <500 U/L or ≥500 U/L | <500 | 48.3 | ≥500 | 15.8 | .02 |
| Serum epo <100 U/L or ≥100 U/L | <100 | 50 | ≥100 | 29.4 | .18 |
| Variable . | Favorable Group . | Response Rate (%) . | Unfavorable Group . | Response Rate (%) . | P Value . |
|---|---|---|---|---|---|
| Sex (M/F)* | Female | 38 | Male | 35 | .93 |
| Karyotype (N/A)3-151 | A | 41 | N | 38 | .81 |
| Pretreatment transfusions (yes/no) | no | 53.3 | yes | 28.6 | .09 |
| Pretreatment transfusions U/month | <2 | 50 | ≥2 | 21.7 | .04 |
| Serum epo <500 U/L or ≥500 U/L | <500 | 48.3 | ≥500 | 15.8 | .02 |
| Serum epo <100 U/L or ≥100 U/L | <100 | 50 | ≥100 | 29.4 | .18 |
*Male/female.
Normal karyotype/abnormal karyotype.